Buybacks in Bloom as Life Science Tools, MDx Firms Deploy Cash | GenomeWeb

By Tony Fong

NEW YORK (GenomeWeb News) – Flush with cash, firms in the life science tools and molecular diagnostics spaces have embarked on stock buyback programs, signaling an end to a hoarding of cash and improving optimism about the state of the economy and their businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.